Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golcadomide + Obinutuzumab in R/R CLL/SLL
NCT04434196Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Dec 2020
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of golcadomide in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), sponsored by Celgene Corporation. Primary endpoints: Dose Limiting Toxicity, Maximum Tolerated Dose and 1 more. Started Dec 2020; status: completed.
02
Drugs
golcadomide
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT04434196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04434196.